☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Discontinue
Merck KGaA and GSK Discontinue P-II INTR@PID BTC 055 Study of Bintrafusp Alfa as 1L Treatment of Biliary Tract Cancer
August 24, 2021
Galapagos and Gilead Discontinue the P-III Trials of Ziritaxestat (GLPG1690) for Idiopathic Pulmonary Fibrosis
February 11, 2021
Santhera Halts P-III SIDEROS Study Evaluating Puldysa in Patients with DMD
October 6, 2020
Halozyme to Discontinue its P-III HALO-301 Study of PEGPH20 for the Treatment of Metastatic Pancreatic Cancer
November 4, 2019
Arbutus to Discontinue its P-Ia/Ib Clinical Study of AB-506 to Treat Patients with Chronic Hepatitis B
October 4, 2019
Acceleron to Discontinue its P-II Study of ACE-083 for Facioscapulohumeral Muscular Dystrophy
September 17, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.